ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX) today announced that two oral presentations will be
presented at the Angiogenesis, Exudation, and Degeneration 2021
conference taking place virtually from February 12 to 13, 2021.
The presentations will be as follows:
Presentation Title: Subretinal Gene Therapy for Exudative
AMD
Presenter: Allen C. Ho, M.D.,
Director of Retina Research at Wills Eye
Hospital and Mid Atlantic Retina
Date/Time: Saturday, February 13,
2021, 9:15 a.m. ET
Presentation Title: Suprachoroidal Gene Therapy for
Exudative AMD and Diabetic Retinopathy
Presenter: Peter A.
Campochiaro, M.D., Director, Retinal Cell and Molecular
Laboratory, Professor of Ophthalmology, The Wilmer Eye
Institute, Johns Hopkins University School of Medicine
Date/Time: Saturday, February 13,
2021, 9:45 a.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Trademarks referenced herein are registered trademarks of
REGENXBIO.
Contacts:
Tricia
Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2021-conference-301222819.html
SOURCE REGENXBIO Inc.